Working… Menu

Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01853982
Recruitment Status : Terminated (Terminated to focus on a larger study within the clinical development program.)
First Posted : May 15, 2013
Results First Posted : June 15, 2015
Last Update Posted : November 16, 2018
Information provided by (Responsible Party):
Cubist Pharmaceuticals LLC

Brief Summary:
This is a Phase 3, multicenter, prospective, randomized, open-label, study to compare the safety and efficacy of intravenous (IV) ceftolozane/tazobactam with that of IV piperacillin/tazobactam in the treatment of ventilator-associated pneumonia (VAP) in adult participants .

Condition or disease Intervention/treatment Phase
Ventilator-Associated Pneumonia (VAP) Drug: Ceftolozane/Tazobactam Drug: Piperacillin/Tazobactam Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam With That of Piperacillin/Tazobactam in Ventilator Associated Pneumonia
Actual Study Start Date : June 14, 2013
Actual Primary Completion Date : November 20, 2013
Actual Study Completion Date : December 8, 2013

Arm Intervention/treatment
Experimental: Ceftolozane/Tazobactam
3000 milligrams (mg) ceftolozane/tazobactam (comprised of 2000 mg ceftolozane and 1000 mg tazobactam), administered intravenously (IV), every 8 hours for 8 days
Drug: Ceftolozane/Tazobactam
Active Comparator: Piperacillin/Tazobactam
4500 mg piperacillin/tazobactam (comprised of 4000 mg piperacillin and 500 mg tazobactam), administered IV, every 6 hours for 8 days
Drug: Piperacillin/Tazobactam
Other Name: Zosyn

Primary Outcome Measures :
  1. Clinical Response at the End of Therapy Visit [ Time Frame: 24 hours after last dose of study drug ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Participant has received mechanical ventilation for > 48 hours
  • Acute Physiology and Chronic Health Evaluation (APACHE) II score of 11-35
  • Presence of a new or progressive infiltrate on chest x-ray
  • Presence of clinical criteria consistent with VAP

Key Exclusion Criteria:

  • History of moderate or severe hypersensitivity reactions to beta-lactam antibiotics
  • Known end stage renal disease or requirement for dialysis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01853982

Layout table for location information
United States, Florida
Jacksonville, Florida, United States
United States, Illinois
Chicago, Illinois, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Minnesota
Duluth, Minnesota, United States
United States, Nebraska
Omaha, Nebraska, United States
United States, New York
Bronx, New York, United States
Jamaica, New York, United States
United States, Ohio
Cleveland, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Abington, Pennsylvania, United States
United States, Tennessee
Nashville, Tennessee, United States
Australia, Queensland
Herston, Queensland, Australia
Meadowbrook, Queensland, Australia
Nambour, Queensland, Australia
Southport, Queensland, Australia
Woolloongabba, Queensland, Australia
New Zealand
Auckland, New Zealand
Christchurch, New Zealand
Wellington, New Zealand
Sponsors and Collaborators
Cubist Pharmaceuticals LLC
Layout table for investigator information
Study Director: Obiamiwe Umeh, MD Cubist Pharmaceuticals LLC
Layout table for additonal information
Responsible Party: Cubist Pharmaceuticals LLC Identifier: NCT01853982    
Other Study ID Numbers: 7625A-009
CXA-NP-11-08 ( Other Identifier: Cubist Study Number )
First Posted: May 15, 2013    Key Record Dates
Results First Posted: June 15, 2015
Last Update Posted: November 16, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia, Ventilator-Associated
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Cross Infection
Piperacillin, Tazobactam Drug Combination
Ceftolozane, tazobactam drug combination
Anti-Bacterial Agents
Anti-Infective Agents
beta-Lactamase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Infective Agents, Urinary
Renal Agents